Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Shree Allada, Richa Parikh, Ajay Nooka, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 4078.

https://doi.org/10.1182/blood-2025-4078

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Om Raval, Lilly Gu, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2025-2812

Published: 2025

Journal Articles

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2025-2811

Published: 2025

Journal Articles

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Dominique Mosley, Richa Parikh, Sara Scott, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2025-3968

Published: 2025

Journal Articles

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Nisha Joseph, Richa Parikh, Shree Allada, Vikas Gupta, Craig Hofmeister, Nishi Shah, Jonathan Kaufman, Sagar Lonial, Ajay Nooka

Blood (2025) 146 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2025-2301

Published: 2025

Journal Articles

Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis

Sheeba Ba Aqeel, Othman Salim Akhtar, Arya Mariam Roy, Alankrita Taneja, Richa Parikh, Muhammad Salman Faisal, Hassan Awada, Andrea Anampa-Guzman, Matthew J Cortese, Francisco Hernandez-Ilizaliturri, Pallawi Torka

Blood (2022) 140 (Supplement 1): 5172–5173.

https://doi.org/10.1182/blood-2022-168164

Published: 2022

Journal Articles

Epidemiology, Survival and Second Primary Malignancies in T-Cell Large Granular Lymphocytic Leukemia

Arya Mariam Roy, Richa Parikh, Muhammad Salman Faisal, Hassan Awada, Karan Jatwani, Paola Ghione

Blood (2022) 140 (Supplement 1): 3698–3699.

https://doi.org/10.1182/blood-2022-168092

Published: 2022

Journal Articles

Spectrum of Second Primary Malignancies in Angioimmunoblastic T-Cell Lymphoma

Richa Parikh, Arya Roy

Blood (2022) 140 (Supplement 1): 3692–3693.

https://doi.org/10.1182/blood-2022-171224

Published: 2022

Journal Articles

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Meera Mohan, MD, Samantha Kendrick, PhD, Yadav Pandey, MD, Richa Parikh, MD, Phil Farmer, Mathew Kottarathara, MD, Shadiqul Hoque, MD, Angel Mitma, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Guido Tricot, MD PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139943

Published: 2020

Journal Articles

Spectrum of Second Primary Malignancies in Pediatric and Adult Langerhans Cell Histiocytosis Cases

Richa Parikh, MD, Ronald S. Go, MD, Gaurav Goyal, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-143279

Published: 2020

Journal Articles

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

David Baker, Milan Bimali, PhD, Luis Carrillo, MD, Archana Sachedina, Daisy Alapat, MD, Md shadiqul Hoque, MD, Mathew Kottarathara, MD, Richa Parikh, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138877

Published: 2020

Journal Articles

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Kristin Larsen, Meera Mohan, MD, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, MD, Richa Parikh, MD, Shadiqul Hoque, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-142527

Published: 2020

Journal Articles

Retrospective Review of Patients with Large Granular Lymphocyte (LGL) Leukemia in a Single Institution over a Period of 11 Years

Kulsum Bano, MD, Manojna Konda, MD, Dinesh Atwal, MD, Richa Parikh, MD, Aneesha Ananthula, MD, Anusha Jillella, MD, Aasiya Matin, MD, Appalanaidu Sasapu, MD

Blood (2019) 134 (Supplement_1): 5279.

https://doi.org/10.1182/blood-2019-131352

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis

Epidemiology, Survival and Second Primary Malignancies in T-Cell Large Granular Lymphocytic Leukemia

Spectrum of Second Primary Malignancies in Angioimmunoblastic T-Cell Lymphoma

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Spectrum of Second Primary Malignancies in Pediatric and Adult Langerhans Cell Histiocytosis Cases

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Retrospective Review of Patients with Large Granular Lymphocyte (LGL) Leukemia in a Single Institution over a Period of 11 Years

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only